As we wrote yesterday, immunotherapy checkpoint inhibitors represent a great advancement and big changes in the management of cancer. It is pertinent, though, to keep in mind that these immuno-oncology products will not be successful with all cancers. Immune checkpoint inhibitors Keytruda (Merck) and Obdivo, Bristol-Myers Squibb and others are already approved around the world for several cancers. We also know that these immunotherapy products would fare much better in combination therapy, provided the products synchronize with each other’s actions, which could demonstrate a better efficacy in a safe way. That’s why immune checkpoint . . .
This content is for paid subscribers.
Today’s Highlights July 8, 2017